Unknown

Dataset Information

Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21.


ABSTRACT: Physiologically based pharmacokinetic (PBPK) modeling has a number of applications, including assessing drug-drug interactions (DDIs) in polymorphic populations, and should be iteratively refined as science progresses. The Simcyp Simulator is annually updated and version 21 included updates to hepatic and intestinal CYP2C19 enzyme abundance, including addition of intermediate and rapid metabolizer phenotypes and changes to the ultra-rapid metabolizer enzyme abundance, with implications for population clearance and DDI predictions. This work details verification of the updates with sensitive CYP2C19 substrates, omeprazole and lansoprazole, using available clinical data from literature. Multiple assessments were performed, including recovery of areas under the concentration-time curve (AUC)

SUBMITTER: Sychterz C 

PROVIDER: S-EPMC9607610 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature